Advanced Drug Delivery Reviews

Article	Citations
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses	757
Editorial board members	395
Emerging antibiotic alternatives: From antimicrobial peptides to bacteriophage therapies	314
Long-acting inhaled medicines: Present and future	310
Recent advances in endocrine organoids for therapeutic application	308
Liposomal formulations for treating lysosomal storage disorders	299
Genome-scale metabolic modelling in antimicrobial pharmacology: Present and future	274
MIDD in Japan– Implementations, challenges and opportunities	262
Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology	252
Models to study basic and applied aspects of lysosomal storage disorders	241
MicroRNAs and their delivery in diabetic fibrosis	201
Tools for computational design and high-throughput screening of therapeutic enzymes	201
Integrating microneedles and sensing strategies for diagnostic and monitoring applications: The state of the art	198
Drug delivery for metabolism targeted cancer immunotherapy	183
Penetration and translocation of functional inorganic nanomaterials into biological barriers	179
Progress on the pathological tissue microenvironment barrier-modulated nanomedicine	174
Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound	164
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders	161
Deciphering albumin-directed drug delivery by imaging	161
Nanoparticle-neutrophils interactions for autoimmune regulation	157
Nanovaccines with cell-derived components for cancer immunotherapy	151
Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies	148
Bacterially mediated drug delivery and therapeutics: Strategies and advancements	147
Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond	146
Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity	145

Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles	141
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity	139
In situ cellular hitchhiking of nanoparticles for drug delivery	139
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria	139
Editorial Board	139
Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease	136
Nanoparticles-mediated ion channels manipulation: From their membrane interactions to bioapplications	135
Targeting microbiome, drug metabolism, and drug delivery in oncology	131
Editorial/Preface	128
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly	126
Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics	124
Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches	123
3D printing of drug delivery systems enhanced with micro/nano-technology	123
Activatable fluorescent probes for real-time imaging-guided tumor therapy	121
Emerging Voices in Drug Delivery – Harnessing and Modulating Complex Biological Systems (Issue 2)	119
Activatable dual-functional molecular agents for imaging-guided cancer therapy	116
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders	115
Synthetic biology-guided design and biosynthesis of protein polymers for delivery	115
RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer	115
Novel strategies for modulating the gut microbiome for cancer therapy	114
Biopharmaceutical drug delivery and phototherapy using protein crystals	113
Ultrasonic particles: An approach for targeted gene delivery	112
Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery	111
Solid implantable devices for sustained drug delivery	110
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers	108
Strategies to develop polymeric microneedles for controlled drug release	108
Drug delivery using gold nanoparticles	108
Lysosomal therapies and drug delivery strategies: An overview	105
Unignored intracellular journey and biomedical applications of extracellular vesicles	104
Tumour extravasation of nanomedicine: The EPR and alternative pathways	102
Soft nano and microstructures for the photomodulation of cellular signaling and behavior	101
The extracellular matrix of hematopoietic stem cell niches	99
Technological and translational challenges for extracellular vesicle in therapy and diagnosis	99
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective	99
In-vitro 3D modelling for charged particle therapy – Uncertainties and opportunities	97
Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases	96
Light sheet fluorescence microscopy for monitoring drug delivery: Unlocking the developmental phases of embryos	96
Micro-patterned cell populations as advanced pharmaceutical drugs with precise functional control	96
Miniaturized therapeutic systems for ultrasound-modulated drug delivery to the central and peripheral nervous system	95
Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies	95
Model-informed precision dosing: State of the art and future perspectives	95
Novel drug delivery systems for the management of dry eye	94
Modular design principle based on compartmental drug delivery systems	94
Fit and forget: The future of dental implant therapy via nanotechnology	91
Engineering complexity in human tissue models of cancer	90
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies	90
Nanobodies: Robust miniprotein binders in biomedicine	89
Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy	89
Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives	89
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers	89

Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors	88
Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer	88
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives	88
Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers	87
Preface: Image-assisted organoid research and application	86
Corrigendum to “Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration” [Adv. Drug Deliv. Rev. 209 (2024) 115328]	86
Editorial Board	85
Gelatin-integrated carbon nanomaterials in nanomedicine: From biosensing and bioprinting to tissue engineering and other biomedical applications	84
Modulating tumor physical microenvironment for fueling CAR-T cell therapy	84
Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy	83
Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory	83
Editorial board members	82
Optical clearing of tissues: Issues of antimicrobial phototherapy and drug delivery	82
Nanoparticles for local delivery of siRNA in lung therapy	82
Editorial board members	81
Corrigendum to ‘Cell-penetrating peptides in protein mimicry and cancer therapeutics’ [Advanced Drug Delivery Reviews, 180 (2022), 114044]	80
Editorial board members	80
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	79
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy	79
Aptamer-based targeted drug delivery and disease therapy in preclinical and clinical applications	79
Listening to drug delivery and responses via photoacoustic imaging	79
Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease	79
Beyond the adverse effects of the systemic route: Exploiting nanocarriers for the topical treatment of skin cancers	79
MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration	79
Design principles for construction of DNA-based nanostructures	79
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment	78
Nanomedicine from amphiphilized prodrugs: Concept and clinical translation	78
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy	77
Recent progress in upconversion nanomaterials for emerging optical biological applications	77
Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes	77
Editorial: Subcellular organelle-targeting of nanomaterials for enhancing therapeutic effectiveness	76
Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability	76
Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles	76
Drug delivery, development, and technological aspects for peripheral drug eluting stents	75
Reversibility and therapeutic development for neurodevelopmental disorders, insights from genetic animal models	75
Recent advances in intelligent oxygen delivery systems for tissue regeneration	75
Additive manufacturing in spatial patterning for spinal cord injury treatment	75
Progress of engineered bacteria for tumor therapy	75
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19	75
Clinical translation of advanced colonic drug delivery technologies	74
Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges	74
Spectral computed tomography with inorganic nanomaterials: State-of-the-art	74
Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery	74
Omics approaches for the assessment of biological responses to nanoparticles	73
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond	73
Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins	72
Editorial Board	71
Microbiota and plant-derived vesicles that serve as therapeutic agents and delivery carriers to regulate metabolic syndrome	71
Recent developments in lactose blend formulations for carrier-based dry powder inhalation	70
The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development	69
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy	69
Nanoarchitectured two-dimensional layered double hydroxides-based nanocomposites for biomedical applications	69
3D extrusion bioprinting of microbial inks for biomedical applications	69
Imaging drug delivery to the lungs: Methods and applications in oncology	69
Synthetic polypeptides for drug and gene delivery, and tissue engineering	69
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound	69
Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration	68
Corrigendum to “Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials” [Adv. Drug Delivery Rev. 192 (2023) 114636]	68
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo	68
Of devices and drugs – Ingestible bots for diagnosis and therapy	68
Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook	68
Intrathecal delivery and its applications in leptomeningeal disease	67
Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics	66
Applications of pharmacometrics in drug development	66
Cell-penetrating peptides in protein mimicry and cancer therapeutics	66
Nanomedicines for the topical treatment of vulvovaginal infections: Addressing the challenges of antimicrobial resistance	66
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy	65
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery	65
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	65
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles	64
Steric stabilization of bioactive nanoparticles using elastin-like polypeptides	64
Microneedle-Mediated Vaccination: Innovation and Translation	63
Corrigendum to “Light sheet fluorescence microscopy for monitoring drug delivery: unlocking the developmental phases of embryos” [Adv Drug Del. Rev. 218 (2025) 115520]	63
Delivery of synthetic mRNAs for tissue regeneration	62
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update	62
Revealing the clinical potential of high-resolution organoids	61
Merging data curation and machine learning to improve nanomedicines	61
Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies	61
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics	61
Special Issue (SI) on: Emerging pharmaceutical technologies (From advanced materials & formulations to new processes) for novel dosage development	60

Editorial board members	60
Microbubble-assisted ultrasound for inner ear drug delivery	60
Laser ablation: Heating up the anti-tumor response in the intracranial compartment	60
Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations	60
Progress of tumor-resident intracellular bacteria for cancer therapy	59
The tendon microenvironment: Engineered in vitro models to study cellular crosstalk	59
Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]	59
Sustained delivery approaches to improving adaptive immune responses	58
Biosafety of mesoporous silica nanoparticles; towards clinical translation	58
Biomaterials releasing drug responsively to promote wound healing via regulation of pathological microenvironment	58
Pancreatic organoids as cancer avatars for true personalized medicine	58
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery	58
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives	57
Editorial Board	57
Next generation concepts in dermal delivery, theranostics, and preclinical testing	57
Editorial Board	57
Editorial board members	56
Cell-based relay delivery strategy in biomedical applications	56
Targeted delivery methods for RNA interference are necessary to obtain a potential functional cure for HIV/AIDS	56
Theme issue: In vitro mucus models	56
Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy	56
Editorial board members	56
Editorial board members	56
Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic	55
Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria	55
Advances in modular control of CAR-T therapy with adapter-mediated CARs	54
Current issues in optical monitoring of drug delivery via hair follicles	54
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits	54
Editorial board members	54
Precise subcellular targeting approaches for organelle-related disorders	54
Recent applications of three-dimensional bioprinting in drug discovery and development	53
Fungal infections: Immune defense, immunotherapies and vaccines	53
Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation	52
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics	52
Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment	52
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer	52
Photonic and magnetic materials for on-demand local drug delivery	52
Biomedical engineering of two-dimensional MXenes	51
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids	51
Long-acting parenteral drug delivery systems for the treatment of chronic diseases	51
Transdermal drug delivery via microneedles to mediate wound microenvironment	51
The RNA-binding protein HuR in human cancer: A friend or foe?	51
Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling	51
The effects of protein corona on in vivo fate of nanocarriers	50
Bioengineering toolkits for potentiating organoid therapeutics	50
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor	50
Stealth and pseudo-stealth nanocarriers	50
Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health	50
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems	50
Novel antimicrobial agents for combating antibiotic-resistant bacteria	49
Effects of nanoparticle deformability on multiscale biotransport	49
Nanomedicine for brain cancer	49
Editorial Board	49
Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies	48
Defensins: The natural peptide antibiotic	48
Microbiome as an immune regulator in health, disease, and therapeutics	48